This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

In the latest close session, Pfizer (PFE) was up +1.16% at $24.51. The stock outpaced the S&P 500's daily gain of 0.53%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq ...

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue ...

Bowing to pressure from Washington, the company is preparing to announce price cuts on drugs for U.S. customers.

This drop brings the stock's year-to-date decline to almost 45%. A key question now is how MRNA's performance compares to ...

Now, it’s worth noting Stock Advisor’s total average return is 1,072% — a market-crushing outperformance compared to 191 % ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

What's the most attractive Big Pharma stock right now for investors? Seeking Alpha analysts weigh in. Read more here.

Today’s Stock Of The Day focuses on Dixon Tech and Pfizer. Dixon Tech is near a strong support level and is expected to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.